Regulatory Consulting Firm: DDReg Pharma

Regulatory Affairs and Pharmacovigilance in Canada Introduction For pharmaceutical and medical device companies entering or expanding in Canada, regulatory compliance is not limited to obtaining a marketing authorization or device licence. It is a continuing lifecycle activity that spans regulatory strategy, submission preparation, safety surveillance, labeling, post-authorization changes, and ongoing interaction with Health Canada. This is where regulatory affairs and pharmacovigilance increasingly intersect. A regulatory strategy may determine how a product enters the Canadian market, while pharmacovigilance activities generate safety evidence that can influence labeling, risk management, regulatory submissions, and post-market decisions. The quality of information flowing between these functions can therefore have a direct impact on compliance and patient safety. Health Canada has also continued to refine its regulatory expectations. Its current guidance on drug submission...

Regulatory Affairs and Pharmacovigilance in India India is a major pharmaceutical and medical device market, but successful market entry involves considerably more than obtaining an initial regulatory approval. Companies must manage regulatory submissions, product quality, safety surveillance, manufacturing changes, labeling, post-approval commitments, and evolving regulatory expectations throughout the product lifecycle. For global pharmaceutical and medical device organizations, this makes Regulatory Affairs (RA) and Pharmacovigilance (PV) closely connected disciplines. Regulatory Affairs helps organizations interpret requirements, prepare submissions, communicate with authorities, and maintain compliance. Pharmacovigilance focuses on identifying, evaluating, understanding, and preventing adverse effects and other medicine-related problems. The World Health Organization describes pharmacovigilance as an essential component of patient safety and public health. For organizati...

Regulatory Affairs and Pharmacovigilance in Hong Kong Hong Kong has a distinct pharmaceutical regulatory environment that global life science companies need to understand before entering or expanding in the market. For pharmaceutical companies, the Department of Health (DH) oversees the safety, efficacy, and quality of medicines marketed in Hong Kong. Pharmaceutical products generally require registration with the Pharmacy and Poisons Board before they can be sold or distributed. At the same time, regulatory compliance does not end with product registration. Companies must consider post-market safety surveillance, regulatory changes, product information, manufacturing documentation, import and export controls, and ongoing lifecycle obligations. This is particularly important in 2026. Hong Kong has begun implementing a phased primary evaluation pathway for certain new drug applications, with Phase 1 taking effect on March 31, 2026. For global pharmaceutical and medical device organizati...